Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rapamycin Response in Tumorigenic and Non-Tumorigenic Hepatic Cell Lines

8 Oct 2009

Abstract excerpt

BACKGROUND: The mTOR inhibitor rapamycin has anti-tumor activity across a variety of human cancers, including hepatocellular carcinoma. However, resistance to its growth inhibitory effects is common. We hypothesized that hepatic cell lines with varying rapamycin responsiveness would show common characteristics accounting for resistance to the drug. METHODOLOGY/PRINCIPAL FINDINGS: We profiled a total of 13 cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to PI3K/AKT/mTOR signaling in cancer
Share to Protein Kinase Regulation and GTPase Signaling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19816606
DOI: 10.1371/journal.pone.0007373

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rapamycin Response in Tumorigenic and Non-Tumorigenic Hepatic Cell LinesPMID 19816606Read ↗

Mechanisms of resistance to rapamycins.Semantic proximity Read ↗

Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.Semantic proximity Read ↗

Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted TherapiesSemantic proximity Read ↗

4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin.Semantic proximity Read ↗

Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumorsSemantic proximity Read ↗

Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.Semantic proximity Read ↗

Translational Regulation in Hepatocellular CarcinogenesisSemantic proximity Read ↗

PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma.Semantic proximity Read ↗

Rapamycin enhances cetuximab cytotoxicity by inhibiting mTOR-mediated drug resistance in mesenchymal hepatoma cells.Semantic proximity Read ↗

Occurrence of Biased mTOR Signaling in Hepatocellular CarcinomaSemantic proximity Read ↗

Context dependent isoform specific PI3K inhibition confers drug resistance in Hepatocellular carcinoma cellsSemantic proximity Read ↗

Resistance to mTOR Kinase Inhibitors in Lymphoma Cells Lacking 4EBP1Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.